ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial

Chen Wei; Tang Xueqing; Liu Qinghua; Chen Weiying; Fu Ping; Liu Fang; Liao Yunhua; Yang Zhenhua; Zhang Jinli; Chen Jian; Lou Tanqi; Fu Junzhou; Kong Yaozhong; Liu Zhengrong; Fan An; Rao Shaoqi; Li Zhibin; Yu Xueqing*广西医科大学; 南方医科大学; 四川大学; 中国人民解放军南京军区福州总医院; 中山大学; 2; 1
AMERICAN JOURNAL OF KIDNEY DISEASES2011-2DOI: 10.1053/j.ajkd.2010.08.036
49被引12阅读
引用收藏
分享

摘要

Background: Intravenous cyclophosphamide with prednisone is an effective treatment for lupus nephritis, but with significant toxicities. We compared the efficacy and safety of tacrolimus versus intravenous cyclophosphamide as induction therapy. <br>Study Design: Multicenter noninferiority randomized controlled trial. <br>Setting & Participants: 81 patients with biopsy-proven lupus nephritis from 9 nephrology centers in China from 2006-2008. <br>Intervention: Prednisone and either tacrolimus (n = 42) or intravenous cyclophosphamide (n = 39) for 6 months. Tacrolimus was started at 0.05 mg/kg/d and titrated to achieve a trough blood concentration of 5-10 ng/mL. Intravenous cyclophosphamide was initiated at 750 mg/m(2) of body surface area, then adjusted to 500-1,000 mg/m(2) every 4 weeks for a total of 6 pulse treatments. <br>Outcomes & Measurements: The primary outcome was complete remission (proteinuria with protein excretion <0.3 g/24 h, serum albumin >= 3.5 g/dL, normal urinary sediment, and normal or stable serum creatinine level) at 6 months. Response (complete or partial remission), clinical parameters, and adverse effects were secondary end points. <br>Results: After the 6-month induction therapy, the tacrolimus group achieved higher cumulative probabilities of complete remission and response (52.4% vs 38.5% and 90.5% vs 82.1%, respectively) than the intravenous cyclophosphamide group, but differences were not statistically significant (log-rank test, P = 0.2 and P = 0.7, respectively). Proteinuria (log-transformed) was significantly decreased in tacrolimus-versus intravenous cyclophosphamide-treated patients after the first month of treatment, even with adjustment for baseline proteinuria (protein excretion, 0.01 vs 0.23 g/d; P = 0.02). After treatment, serum creatinine levels and estimated glomerular filtration rates were not significantly different between treatment groups. Adverse effects, such as leukopenia and gastrointestinal symptoms, were less frequent in the tacrolimus group. <br>Limitations: Nonblinded, small sample size, and short duration of follow-up. <br>Conclusions: In conjunction with prednisone, induction therapy with tacrolimus is at least as efficacious as intravenous cyclophosphamide and prednisone in producing complete remission of lupus nephritis and has a more favorable safety profile. Am J Kidney Dis. 57(2):235-244.

学科与关键词

关键词
Tacrolimuscyclophosphamidelupus nephritisrandomized controlled trial
相关
加载中…
  • Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study
    Zhang, Shuoyang; Qiu, Qian; Zeng, Shan; Li, Hao; Xu, Liujing; Jie, Ligang; Hu, Xuejun; Xiao, Youjun; Chen, Dongying; Zhan, Zhongping; Liang, Liuqin*; Yu, Qinghong*; Xu, Hanshi*CLINICAL RHEUMATOLOGY, 2023.
  • Effectiveness and safety of tripterygium glycosides tablet (SIC)) for lupus nephritis: a systematic review and Meta-analysis
    Zhou, Yingyan; Liang, Huasheng; Yan, Jingyao; He, Xiaohong; Pan, Lili; Li, Xue; Chen, Xianghong; Chen, Xiumin; Yang, Aicheng*; Huang, Qingchun*Journal of Traditional Chinese Medicine, 2022, 42(5): 671-680.被引 3
  • Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy
    Liu, Diankun; Zhou, Qiang; Wang, Di; Qu, Yuan; Guo, Qihong; Wen, Jing; Yu, Qinghong*; Ai, Jun*Lupus, 2022, 31(12): 1456-1467.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
发表日期
2011-02
卷期
第 57 卷, 第 2 期
页码
235-244
DOI
10.1053/j.ajkd.2010.08.036
语言
ENGLISH
成果收录
SCI
资助标注
Scientific and Technologic Committee of Guangdong province [2006A36001002]; Department of Health, Guangzhou City [2007-ZDa-01]; Ministry of Education, Peoples' Republic of China [IRT0870]; Sun Yat-sen University; Astellas Pharmaceuticals

作者

  • C

    Chen Wei (第一作者)

    1

  • T

    Tang Xueqing

    1

查看全部 18 位作者收起作者
  • L

    Liu Qinghua

    1

  • C

    Chen Weiying

    1

  • F

    Fu Ping

    sichuan univ

  • L

    Liu Fang

    sichuan univ

  • L

    Liao Yunhua

    1

  • Y

    Yang Zhenhua

    1

  • Z

    Zhang Jinli

  • C

    Chen Jian

    fuzhou gen hosp

  • L

    Lou Tanqi

    sun yat sen univ

  • F

    Fu Junzhou

  • K

    Kong Yaozhong

  • L

    Liu Zhengrong

    so med univ

  • F

    Fan An

    sun yat sen univ

  • R

    Rao Shaoqi

    sun yat sen univ

  • L

    Li Zhibin

    1

  • Y

    Yu Xueqing (通讯)

    1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417